S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Alphatec (ATEC) Stock Forecast, Price & News

-0.45 (-5.48%)
(As of 05/20/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.31 million shs
Average Volume
793,184 shs
Market Capitalization
$789.66 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ATEC News and Ratings via Email

Sign-up to receive the latest news and ratings for Alphatec and its competitors with MarketBeat's FREE daily newsletter.

Alphatec logo

About Alphatec

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.


Alphatec (NASDAQ:ATEC) Shares Gap Up on Analyst Upgrade
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$243.21 million
Book Value
$0.41 per share


Net Income
$-144.33 million
Pretax Margin




Free Float
Market Cap
$789.66 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

2.38 out of 5 stars

Medical Sector

211th out of 1,420 stocks

Surgical & Medical Instruments Industry

24th out of 138 stocks

Analyst Opinion: 3.4Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -

Alphatec (NASDAQ:ATEC) Frequently Asked Questions

Is Alphatec a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Alphatec stock.
View analyst ratings for Alphatec
or view top-rated stocks.

When is Alphatec's next earnings date?

Alphatec is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Alphatec

How were Alphatec's earnings last quarter?

Alphatec Holdings, Inc. (NASDAQ:ATEC) posted its quarterly earnings results on Thursday, May, 5th. The medical technology company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.14. The medical technology company earned $70.93 million during the quarter, compared to the consensus estimate of $67.72 million. Alphatec had a negative trailing twelve-month return on equity of 147.10% and a negative net margin of 60.83%.
View Alphatec's earnings history

What guidance has Alphatec issued on next quarter's earnings?

Alphatec issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $316.00 million-$316.00 million, compared to the consensus revenue estimate of $304.91 million.

What price target have analysts set for ATEC?

5 equities research analysts have issued 12 month price objectives for Alphatec's stock. Their forecasts range from $12.50 to $22.50. On average, they anticipate Alphatec's stock price to reach $18.17 in the next twelve months. This suggests a possible upside of 134.1% from the stock's current price.
View analysts' price targets for Alphatec
or view top-rated stocks among Wall Street analysts.

Who are Alphatec's key executives?
Alphatec's management team includes the following people:
  • Mr. Patrick S. Miles, Exec. Chairman, CEO & Pres (Age 56, Pay $1.46M) (LinkedIn Profile)
  • Mr. Craig E. Hunsaker, Exec. VP of People & Culture, Corp. Sec. and Gen. Counsel (Age 58, Pay $711.95k) (LinkedIn Profile)
  • Mr. David P. Sponsel, Exec. VP of Sales (Age 43, Pay $794.18k)
  • Mr. J. Todd Koning, Exec. VP & CFO (Age 49)
  • Mr. Brian R. Snider, Exec. VP of Marketing (Age 44)
  • Mr. Jonathan Allen, Exec. VP of Commercial Operations (Age 62)
  • Mr. Scott Lish, Sr. VP of R&D (Age 40) (LinkedIn Profile)
  • Dr. Luiz Pimenta, Chief Medical Officer
  • Ms. Kelli Mari Howell, Exec. VP of Clinical Strategies (Age 48)
  • Mr. Eric Dasso, Exec. VP of Adjunctive Technologies (Age 48)
What is Pat Miles' approval rating as Alphatec's CEO?

7 employees have rated Alphatec CEO Pat Miles on Glassdoor.com. Pat Miles has an approval rating of 72% among Alphatec's employees.

What other stocks do shareholders of Alphatec own?
What is Alphatec's stock symbol?

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

Who are Alphatec's major shareholders?

Alphatec's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.86%), Vanguard Group Inc. (3.37%), First Light Asset Management LLC (2.67%), Next Century Growth Investors LLC (2.09%), State Street Corp (1.94%) and Royal Bank of Canada (1.21%). Company insiders that own Alphatec stock include Craig E Hunsaker, David H Mowry, David R Pelizzon, David Sponsel, Evan Bakst, James L L Tullis, James L L Tullis, Jason Hochberg, Jeffrey G Black, Jennifer N Pritzker, Jennifer N Pritzker, Patrick Miles, Paul Segal and Scott Lish.
View institutional ownership trends for Alphatec

Which institutional investors are selling Alphatec stock?

ATEC stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., JPMorgan Chase & Co., Rothschild & Co. Asset Management US Inc., Jacob Asset Management of New York LLC, State Street Corp, Granite Point Capital Management L.P., Goldman Sachs Group Inc., and New York State Common Retirement Fund. Company insiders that have sold Alphatec company stock in the last year include David H Mowry, David Sponsel, James L L Tullis, Patrick Miles, and Scott Lish.
View insider buying and selling activity for Alphatec
or view top insider-selling stocks.

Which institutional investors are buying Alphatec stock?

ATEC stock was bought by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, King Luther Capital Management Corp, Waypoint Capital Advisors LLC, Pier Capital LLC, Parkman Healthcare Partners LLC, Polar Asset Management Partners Inc., Principal Financial Group Inc., and Next Century Growth Investors LLC. Company insiders that have bought Alphatec stock in the last two years include Craig E Hunsaker, David R Pelizzon, Evan Bakst, Jason Hochberg, Jennifer N Pritzker, Patrick Miles, and Paul Segal.
View insider buying and selling activity for Alphatec
or or view top insider-buying stocks.

How do I buy shares of Alphatec?

Shares of ATEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alphatec's stock price today?

One share of ATEC stock can currently be purchased for approximately $7.76.

How much money does Alphatec make?

Alphatec has a market capitalization of $789.66 million and generates $243.21 million in revenue each year. The medical technology company earns $-144.33 million in net income (profit) each year or ($1.65) on an earnings per share basis.

How many employees does Alphatec have?

Alphatec employs 561 workers across the globe.

When was Alphatec founded?

Alphatec was founded in 1990.

What is Alphatec's official website?

The official website for Alphatec is www.atecspine.com.

How can I contact Alphatec?

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The medical technology company can be reached via phone at (760) 431-9286, via email at [email protected], or via fax at 800-922-1356.

This page was last updated on 5/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.